Login to Your Account

HCV Buyout Target Achillion Pads Coffers in $42M Offering

By Jennifer Boggs
Managing Editor

Tuesday, September 4, 2012

The recent spate of setbacks for competitors working in hepatitis C virus (HCV) has proved good news for Achillion Pharmaceuticals Inc., which took the opportunity to shore up its balance sheet with a $41.8 million offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription